ArticleMaterials today. Bio2026
SynClear: A one-step synchronous clearing and labeling strategy for multiscale 3D brain mapping.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-resolution three-dimensional imaging is essential for resolving the multiscale organization of biological tissues. However, conventional workflows treat tissue clearing and molecular labeling as separate steps, leading to a kinetic mismatch between reagent transport and probe binding that limits imaging depth, labeling uniformity, and throughput. Here, we introduce SynClear, a one-step strategy that synchronizes nuclear labeling with tissue clearing by embedding fluorescent probes within a chemically engineered clearing medium. This integrated formulation enables rapid and uniform labeling across millimeter-scale samples while preserving endogenous fluorescence and remaining compatible with multiplexed immunostaining. We demonstrate the general applicability of SynClear across diverse tissue types, including mouse brain, peripheral organs, and post-mortem human cortex. In mouse brain sections, SynClear supports accurate 3D atlas registration and quantitative mapping of cytoarchitecture. In glioblastoma models, it resolves pathological features across scales, from tumor boundaries to immune microenvironments. In human cortex, it enables laminar-resolved structural analysis and neuronal subtype mapping. By coupling labeling and clearing within a single chemical framework, SynClear provides a robust and scalable platform for volumetric tissue imaging, with potential applications in both basic neuroscience and translational pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.